Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
Terminated · Phase 1 · NCT02203773
Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
At a glance
- Research payments reported, 2025
- $160,500
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 212
About the trial
- Sponsor
- AbbVie (with Genentech, Inc.)
- Tested
- Posaconazole (drug), ABT-199 (drug), Decitabine (drug), Azacitidine (drug)
- Dates
- Started 2014-10-06; completion 2022-06-16
- Results posted
- Not yet
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.
From ClinicalTrials.gov, last updated 2023-05-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $160,500 in research payments for this study in 2025 (2 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baylor College of Medicin $80,250
- Baylor College of Medicine $80,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.